Articles

Clofarabine, high-dose cytarabine and liposomal daunorubicin in pediatric relapsed/refractory acute myeloid leukemia: a phase IB study

Department of Pediatric Oncology/Hematology, Erasmus MC-Sophia Children’s Hospital, Rotterdam, the Netherlands;Department of Pediatric Oncology, Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands;European Consortium for Innovative Therapies for Children with Cancer (ITCC), Villejuif, France
Department of Pediatric Oncology, University Children’s Hospital, Essen, Germany
Centre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, UK
Children’s Cancer Research Institute and St. Anna Children’s Hospital, Department of Pediatrics, Medical University of Vienna, Austria
Pediatric Hematology/Oncology, Johann Wolfgang Goethe University, Frankfurt, Germany
Pediatric Hematology and Oncology, University Children’s Hospital, Münster, Germany
Department of Pediatric Hematology and Oncology, AP-HP, GH HUEP, Trousseau Hospital, Paris, France
Department of Pediatric Hematology and Oncology, 2ndFaculty of Medicine, Charles University Prague, University Hospital Motol, Czech Republic
Department of Pediatric Oncology, University Medical Center Groningen, University of Groningen, the Netherlands
Clinical Trial Center, Department of Hematology, Erasmus Medical Center, Rotterdam, the Netherlands
Pediatric Hematology Department, IHOP and Claude Bernard University, Lyon, France
Department of Pediatric Hematology, Robert Debré Hospital, Paris, France
Division of Pediatric Hematology and Oncology, Department of Pediatrics and Adolescent Medicine, University of Freiburg, Germany
Department of Pediatric Oncology/Hematology, Erasmus MC-Sophia Children’s Hospital, Rotterdam, the Netherlands;European Consortium for Innovative Therapies for Children with Cancer (ITCC), Villejuif, France
Department of Pediatric Oncology, Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands;Department of Pediatric Oncology, VU University Medical Center, Amsterdam, the Netherlands;I-BFM-AML committee, Kiel, Germany
European Consortium for Innovative Therapies for Children with Cancer (ITCC), Villejuif, France;I-BFM-AML committee, Kiel, Germany
Department of Pediatric Oncology/Hematology, Erasmus MC-Sophia Children’s Hospital, Rotterdam, the Netherlands;Department of Pediatric Oncology, Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands;European Consortium for Innovative Therapies for Children with Cancer (ITCC), Villejuif, France
Vol. 103 No. 9 (2018): September, 2018 https://doi.org/10.3324/haematol.2017.187153